UnknownPHASE1, PHASE2NCT04365101

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Studying Adult acute respiratory distress syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Celularity Incorporated
Principal Investigator
Corey Casper, MD MPH
Access to Advanced Health Institute (AAHI)
Intervention
CYNK-001(biological)
Enrollment
86 enrolled
Eligibility
18 years · All sexes
Timeline
20202022

Study locations (7)

Collaborators

Access to Advanced Health Institute (AAHI) · Lung Biotechnology PBC · California Institute for Regenerative Medicine (CIRM)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04365101 on ClinicalTrials.gov

Other trials for Adult acute respiratory distress syndrome

Additional recruiting or active studies for the same condition.

See all trials for Adult acute respiratory distress syndrome

← Back to all trials